α-Synuclein and Lewy pathology in Parkinson's disease

Current Opinion in Neurology

Volumn 28, Issue 4, 2015, Pages 375-381

  Kalia, Lorraine V ^a,c,d   Kalia, Suneil K ^b,d  

^a Division of Neurology   (Canada)

^b Neurosurgery   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

LRRK2; neurodegeneration; oligomers; prion; protein aggregation

Indexed keywords

ALPHA SYNUCLEIN;

HUMAN; LEWY BODY; MOLECULAR PATHOLOGY; NONHUMAN; PARKINSON DISEASE; PROTEIN CONFORMATION; REVIEW; BRAIN; METABOLISM; NERVE CELL; PATHOLOGY;

ALPHA-SYNUCLEIN; BRAIN; HUMANS; LEWY BODIES; NEURONS; PARKINSON DISEASE;

EID: 84941195662     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000215     Document Type: Review

References (42)

1. Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol 2012; 9:13-24.
2. Deleersnijder A, Gerard M, Debyser Z, Baekelandt V. The remarkable con-formational plasticity of alpha-synuclein: blessing or curse? Trends Mol Med 2013; 19:368-377.
3. Gould N, Mor DE, Lightfoot R, et al. Evidence of native a-synuclein conformers in the human brain. J Biol Chem 2014; 289:7929-7934.
4. Cremades N, Cohen SIA, Deas E, et al. Direct observation of the interconver-sion of normal and toxic forms of a-synuclein. Cell 2012; 149:1048-1059.
5. Ghosh D, Singh PK, Sahay S, et al. Structure based aggregation studies reveal the presence of helix-rich intermediate during a-synuclein aggregation. Sci Rep 2015; 5:9228.
6. Kalia LV, Kalia SK, McLean PJ, et al. a-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol 2013; 73:155-169.
7. Pacheco CR, Morales CN, Ramírez AE, et al. Extracellular a-synuclein alters synaptic transmission in brain neurons by perforating the neuronal plasma membrane. J Neurochem 2015; 132:731-741.
8. Betzer C, Movius AJ, Shi M, et al. Identification of synaptosomal proteins binding to monomeric and oligomeric a-synuclein. PLoS One 2015; 10:e0116473.
9. Choi B-K, Choi M-G, Kim J-Y, et al. Large a-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc Natl Acad Sci 2013; 110:4087-4092.
10. Prots I, Veber V, Brey S, et al. a-Synuclein oligomers impair neuronal microtubule-kinesin interplay. J Biol Chem 2013; 288:21742-21754.
11. Rockenstein E, Nuber S, Overk CR, et al. Accumulation of oligomer-prone a-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain 2014; 137:1496-1513.
12. Recasens A, Dehay B. Alpha-synuclein spreading in Parkinson's disease. Front Neuroanat 2014; 8:159.
13. Luk KC, Kehm VM, Zhang B, et al. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synu-cleinopathy in mice. J Exp Med 2012; 209:975-986.
14. Luk KC, Kehm V, Carroll J, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012; 338:949-953.
15. Recasens A, Dehay B, Bové J, et al. Lewy body extracts from Parkinson disease brains trigger a-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 2014; 75:351-362.
16. Sacino AN, Brooks M, Thomas MA, et al. Intramuscular injection of a-synuclein induces CNS a-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc Natl Acad Sci 2014; 111:10732-10737.
17. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of a-synuclein. Proc Natl Acad Sci 2009; 106:13010-13015.
18. Hansen C, Angot E, Bergström A-L, et al. a-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011; 121:715-725.
19. Kordower JH, Dodiya HB, Kordower AM, et al. Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis 2011; 43:552-557.
20. Rey NL, Petit GH, Bousset L, et al. Transfer of human a-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol 2013; 126:555-573.
21. Gurry T, Ullman O, Fisher CK, et al. The dynamic structure of a-synuclein multimers. J Am Chem Soc 2013; 135:3865-3872.
22. Osterberg VR, Spinelli KJ, Weston LJ, et al. Progressive aggregation of alpha-synuclein and selective degeneration of Lewy inclusion-bearing neurons in a mouse model of parkinsonism. Cell Rep 2015; 10:1252-1260.
23. Kalia LV, Lang AE. Parkinson's disease. Lancet 2015; doi: 10.1016/S0140-6736(14)61393-3 [Epub ahead of print]
24. Wakabayashi K, Tanji K, Odagiri S, et al. The Lewy body in Parkinson's disease and related neurodegenerative disorders. Mol Neurobiol 2013; 47:495-508.
25. Appel-Cresswell S, Rajput AH, Sossi V, et al. Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism. Mov Disord 2014; 29:1684-1687.
26. Funayama M, Ohe K, Amo T, et al. CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study. Lancet Neurol 2015; 14:274-282.
27. Krebs CE, Karkheiran S, Powell JC, et al. The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive parkinsonism with generalized seizures. Hum Mutat 2013; 34:1200-1207.
28. Quadri M, Fang M, Picillo M, et al. Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset parkinsonism. Hum Mutat 2013; 34:1208-1215.
29. Wilson GR, Sim JCH, McLean C, et al. Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with a-synuclein pathology. Am J Hum Genet 2014; 95:729-735.
30. Butcher NJ, Kiehl T-R, Hazrati L-N, et al. Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol 2013; 70:1359-1366.
31. Guerreiro PS, Huang Y, Gysbers A, et al. LRRK2 interactions with a-synuclein in Parkinson's disease brains and in cell models. J Mol Med 2013; 91:513-522.
32. Tsika E, Glauser L, Moser R, et al. Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration. Hum Mol Genet 2014; 23:4621-4638.
33. Vilarino-Guell C, Rajput A, Milnerwood AJ, et al. DNAJC13 mutations in Parkinson disease. Hum Mol Genet 2014; 23:1794-1801.
34. Fujioka S, Sundal C, Strongosky AJ, et al. Sequence variants in eukaryotic translation initiation factor 4-g (eIF4G1) are associated with Lewy body dementia. Acta Neuropathol 2013; 125:425-438.
35. Murphy KE, Cottle L, Gysbers AM, et al. ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathol Com-mun 2013; 1:11.
36. Zhao T, Severijnen L-A, van der Weiden M, et al. FBXO7 immunoreactivity in a-synuclein-containing inclusions in Parkinson disease and multiple system atrophy. J Neuropathol Exp Neurol 2013; 72:482-488.
37. Goker-Alpan O, Stubblefield BK, Giasson BI, Sidransky E. Glucocerebrosi-dase is present in a-synuclein inclusions in Lewy body disorders. Acta Neuropathol 2010; 120:641-649.
38. Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson's disease. Mov Disord 2012; 27:831-842.
39. Doherty KM. Parkin disease: a clinicopathologic entity? JAMA Neurol 2013; 70:571-579.
40. Kalia LV, Lang AE, Hazrati L-N, et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol 2015; 72:100.
41. Gomez A, Ferrer I. Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment. Acta Neuropathol 2010; 120:155-167.
42. Mamais A, Raja M, Manzoni C, et al. Divergent a-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology compared to idiopathic cases. Neurobiol Dis 2013; 58:183-190.